Bethan Kilpatrick
About Bethan Kilpatrick
Bethan Kilpatrick is a Principal Scientist at BenevolentAI with extensive experience in molecular and cellular pharmacology and a strong academic background in neuroscience and biology.
Current Title and Role
Bethan Kilpatrick is currently a Principal Scientist at BenevolentAI. In her current role, she applies her extensive expertise in molecular and cellular pharmacology. Her responsibilities likely include overseeing research projects, contributing to scientific publications, and collaborating with other scientists and researchers.
Previous Roles at BenevolentAI
Bethan Kilpatrick initially joined BenevolentAI in 2019 as a Molecular and Cellular Pharmacologist. In this role, she focused on exploring the intricate details of molecular and cellular interactions. After two years, she transitioned to her current role as Principal Scientist, continuing to build on her experience in pharmacology to drive forward various research initiatives.
Research Associate at University College London
Prior to joining BenevolentAI, Bethan Kilpatrick worked as a Research Associate at University College London from 2015 to 2019. During her tenure, she was involved in numerous significant research projects in the field of neuroscience. Her work contributed to the advancement of scientific understanding and provided valuable data for ongoing studies.
Educational Background in Neuroscience and Biology
Bethan Kilpatrick has a strong academic background in the sciences. She holds a Doctor of Philosophy (PhD) in Neuroscience from University College London, which she earned between 2011 and 2015. Additionally, she has a Master of Science (MSc) in Neuroscience from University College London, completed in 2011. Her academic journey began with a Bachelor of Science (BSc) in Biology from The University of Sheffield, obtained between 2007 and 2010.
Experience in Molecular and Cellular Pharmacology
Bethan Kilpatrick has extensive experience in molecular and cellular pharmacology. Her work in this field has been integral to her roles at BenevolentAI, where she has contributed to research aimed at understanding complex biological processes. Her expertise in pharmacology combines with her academic background to drive forward impactful scientific research.